Table 1.
Clinical characteristics and SARS-CoV2 serological findings in studied groups stratified by type-2 diabetes mellitus status.
| Non-diabetics | Diabetics | Overall | |
| (N=181) | (N=81) | (N=262) | |
| Age (years) | |||
| Mean (SD) | 44.8 (13.2) | 59.4 (12.0) | 49.3 (14.5) |
| Median (Min, Max) | 43.1 [21.0, 87.4] | 60.3 [24.4, 81.2] | 50.3 [21.0, 87.4] |
| Gender | |||
| Female | 92 (50.8%) | 34 (42.0%) | 126 (48.1%) |
| Male | 89 (49.2%) | 47 (58.0%) | 136 (51.9%) |
| BMI categories | |||
| Less than 25 | 51 (28.2%) | 14 (17.3%) | 65 (24.8%) |
| Between 25 and 30 | 83 (45.9%) | 34 (42.0%) | 117 (44.7%) |
| Greater than 30 | 43 (23.8%) | 31 (38.3%) | 74 (28.2%) |
| Missing | 4 (2.2%) | 2 (2.5%) | 6 (2.3%) |
| Hypertension | |||
| No | 151 (83.4%) | 42 (51.9%) | 193 (73.7%) |
| Yes | 30 (16.6%) | 39 (48.1%) | 69 (26.3%) |
| Comorbidity score | |||
| Mean (SD) | 0.320 (0.594) | 0.469 (0.896) | 0.366 (0.703) |
| Median (Min, Max) | 0 [0, 3.00] | 0 [0, 5.00] | 0 [0, 5.00] |
| Previous infection of COVID 19 | |||
| No | 155 (85.6%) | 69 (85.2%) | 224 (85.5%) |
| Yes | 26 (14.4%) | 12 (14.8%) | 38 (14.5%) |
| Duration since second dose | |||
| Mean (SD) | 84.3 (37.1) | 81.5 (37.4) | 83.4 (37.2) |
| Median (Min, Max) | 82.0 [7.00, 148] | 81.0 [13.0, 148] | 82.0 [7.00, 148] |
| IgG (BAU/ml) | |||
| Mean (SD) | 154 (49.1) | 138 (59.4) | 149 (52.9) |
| Median (Min, Max) | 160 [11.0, 243] | 140 [19.3, 264] | 156 [11.0, 264] |
| IgM (BAU/ml) | |||
| Mean (SD) | 65.6 (84.2) | 58.1 (112) | 63.3 (93.6) |
| Median (Min, Max)( | 31.3 [0.600, 600] | 30.5 [0, 800] | 31.0 [0, 800] |
| Neutralizing antibodies (%) | |||
| Mean (SD) | 87.1 (11.6) | 79.7 (19.5) | 84.8 (14.9) |
| Median (Min, Max) | 91.5 [22.6, 95.3] | 88.0 [0, 95.8] | 90.9 [0, 95.8] |
| Missing | 3 (1.7%) | 0 (0%) | 3 (1.1%) |